<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03106246</url>
  </required_header>
  <id_info>
    <org_study_id>15-582-MUHC</org_study_id>
    <nct_id>NCT03106246</nct_id>
  </id_info>
  <brief_title>Circulating Extracellular Vesicles Released by Human Islets of Langerhans</brief_title>
  <official_title>Immune Response to Extracellular Vesicles Released by Human Islets of Langerhans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Beta-cells release extracellular vesicles (EV) and exosomes under normal and pathophysiologic
      conditions. These EV contain beta-cell specific autoantigens which may trigger the immune
      response at the initiation of type 1 diabetes. In this study, beta-cell derived EV will be
      detected and characterized in human blood samples.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult subjects will be recruited with: new onset type 1 diabetes mellitus (T1DM), type 2
      diabetes mellitus (T2DM) as well as islet transplant candidates. Blood samples will be
      collected at defined intervals to determine beta-cell specific EV and determine the utility
      of this biomarker as a measure of beta-cell stress or injury.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the levels of circulating EVs</measure>
    <time_frame>2 years</time_frame>
    <description>Based on well-known EV markers, subject plasma samples will be characterized to determine whether these EVs are detectable using small particle flow cytometry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine whether these EVs contain islet-specific antigens</measure>
    <time_frame>2 years</time_frame>
    <description>EVs will be further characterized using small particle flow cytometry for known islet-specific antigens such as GAD65 and ZnT8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mutivariate analysis will be performed with patient parameters and EV parameters</measure>
    <time_frame>3 years</time_frame>
    <description>Correlate levels of EVs containing islet specific markers to patient parameters like age, duration of established diabetes, levels of autoantibodies,</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type1 Diabetes Mellitus</condition>
  <condition>Type2 Diabetes</condition>
  <condition>Islet Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>New onset T1DM</arm_group_label>
    <description>Newly diagnosed Type I diabetic patients who are hyperglycemic but still C-peptide positive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T1DM</arm_group_label>
    <description>Patients with established type I diabetes. they are hyperglycemic but C-peptide negative</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM</arm_group_label>
    <description>Patients with established type II diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Islet Transplant</arm_group_label>
    <description>Patients who received an islet transplantation for type I diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <description>Normoglycemic healthy volunteers</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood samples. Cellular component will be retained for studies using subject
      specific peripheral blood mononuclear cells. EV will be purified from plasma and also
      retained separately.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with confirmed Type I and Type II diabetes, patients undergoing islet
        transplantation and healthy volunteers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age 18-70 Diagnosis of type 1 diabetes or type 2 diabetes or islet transplant recipient

        Exclusion Criteria:

        Unknown diagnosis of diabetes Active infection Immunocompromised Organ transplant
        recipients not including candidates for islet transplant HIV+ Hepatitis C+ Hepatitis B
        surface antigen+ Known concurrent malignancy Known pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarita Negi</last_name>
      <phone>514-934-1934</phone>
      <email>Sarita.negi@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Steven Paraskevas, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2017</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Center</investigator_affiliation>
    <investigator_full_name>Dr. Steven Paraskevas</investigator_full_name>
    <investigator_title>Associate Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>Extracellular vesicles</keyword>
  <keyword>Autoimmunity</keyword>
  <keyword>Beta-cell injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Blister</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

